Sangeeta Yadav et al JMSCR Volume 08 Issue 01 January 2020 Page 477 JMSCR Vol||08||Issue||01||Page 470-482||January 2020 Efficacy of Rifaximin in patients with Irritable Bowel Syndrome and its Comparison with Previous Drugs: A Retrospective Study Authors Sangeeta Yadav 1 Omkar Singh 2 , Manoj Kumar 3 , Ashish Gautam 4 1 Tutor, Autonomous State Medical College, Firozabad 2 Assistant Professor, Autonomous State Medical College, Firozabad 3 Associate Professor, Autonomous State Medical College, Firozabad 4 Associate Professor, SN Medical College, Agra Abstract Irritable bowel syndrome often becomes a headache for the patient as well as doctor and till date no drug has proven to be 100% effective in managing these patients. We studied Rifaximin, one of the latest drug for the management of this disorder and compared it with drugs previously used. This study, a combination of retrospective as well as prospective showed that Rifaximin has the most satisfactory results in these patients, however the results were not sustained as with other drugs. Introduction I.B.S. is a disorder that leads to abdominal pain and cramping and changes in bowel movements 1 and other symptoms in the absence of any organic cause 2 or detectable structural abnormality. The IBS is one of the most common chronic medical conditions, yet its cause is unknown. It is a source of chronic pain, fatigue, and other symptoms 3,4 anxiety, depression 5,6 which may lead to suicide 7 . Proposed factors for suicide are hopelessness and poor quality of services 8,9 .Patients with I.B.S. fall into two groups. 10 • Most commonly, patients have abdominal pain associated with altered bowel habits that consist of constipation, diarrhoea, or both. • In second group, the patients have painless diarrhoea. Painless diarrhoea does not strictly fulfil the Rome-II criteria to be classified as I.B.S. A large number of drugs have been used for the treatment of IBS till date but none of them has proved to be successful. We studied the effect of Rifaximin in these patients and compared its effect with the drugs previously used. Rifaximin is a semisynthetic antibiotic used for treating traveler’s diarrhoea 11 & hepatic encephalopathy. Material and Methods Inclusion Criteria Patients who fulfill the ROME 3 Criteria for diagnosis of IBS-D, or Patients attending the OPD having complaints suggestive of IBS-D and did not respond with oral anti-amoebic and gut specific antibiotics, or Patients previously labeled IBS-D after essential investigations and did not respond with previous treatment and between 20 to 50 years of age were included in the study. http://jmscr.igmpublication.org/home/ ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v8i1.74